Prime Therapeutics employees seek professional and personal development with Women’s Health Leadership TRUST membership

Network supports growth, well-being and success of members throughout their leadership journey

July 27, 2022

Prime Therapeutics (Prime) selected five employees for a company-sponsored membership with the Women’s Health Leadership TRUST (the TRUST) based on their leadership attributes, dedication to the health care industry and commitment to advancing women in health care.

Christine Bent, senior vice president and chief operating officer at Prime, serves as the immediate past president on the TRUST’s board of directors. The organization’s mission is to be an inclusive, diverse and collaborative network that advocates, inspires and offers insights to women leaders in health care.

“The TRUST is a great way for women to foster their leadership skills and continue to grow,” Bent said. “It’s exciting that Prime with our Diversity & Inclusion (D&I) Council are giving these employees a development opportunity that contributes to the advancement of women in health care.”

Prime employees new to the TRUST may take advantage of member benefits including networking, professional and personal development and ongoing education and events. Other opportunities include a mentoring program and volunteer committee participation.

Recipients of a one-year membership were nominated by their peers. Member selection was finalized by a review panel of Prime executive and D&I Council leaders.

Prime’s newest members of the TRUST will join the over 400 members that continue to draw on the vision to “Create new possibilities for all women – in health care, well-being and beyond.”

Find out more about Christine’s passion for fostering an environment of sponsorship and the work of the TRUST.

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion